Stock OGN ORGANON & CO.
Add to a list
To use this feature you must be a member
Log inSign up

Organon & Co. Stock

Equities

OGN

US68622V1061

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 16:00:02 2024-04-26 EDT 		5-day change 1st Jan Change
18.55 USD +0.71% Intraday chart for Organon & Co. +4.10% +28.64%
04-09 Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating MT
04-08 Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint MT

Financials

Sales 2024 * 6.37B 8.71B Sales 2025 * 6.46B 8.83B Capitalization 4.77B 6.52B
Net income 2024 * 788M 1.08B Net income 2025 * 981M 1.34B EV / Sales 2024 * 1.92 x
Net Debt 2024 * 7.5B 10.25B Net Debt 2025 * 6.83B 9.33B EV / Sales 2025 * 1.8 x
P/E ratio 2024 *
6.1 x
P/E ratio 2025 *
4.89 x
Employees 10,000
Yield 2024 *
5.97%
Yield 2025 *
6.2%
Free-Float 99.86%
More Fundamentals * Assessed data

Chart Organon & Co.

Dynamic Chart

Latest news about Organon & Co.

Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating MT
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint MT
Aurobindo Pharma Gets US FDA Final Nod for Mometasone Furoate Monohydrate Nasal Spray MT
Philips: new CFO in October CF
New York attorney general urges stronger safety warning on asthma drug Singulair RE
Organon's Hadlima Chosen by VA as Substitute for Humira MT
Goldman Sachs Adjusts Price Target on Organon to $18 From $16, Keeps Neutral Rating MT
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary CI
US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary CI
Sector Update: Health Care Stocks Edge Higher Premarket Thursday MT
Organon's Q4 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance Issued MT
Transcript : Organon & Co., Q4 2023 Earnings Call, Feb 15, 2024
Organon & Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Earnings Flash (OGN) ORGANON & CO. Posts Q4 Revenue $1.6B, vs. Street Est of $1.48B MT
Earnings Flash (OGN) ORGANON & CO. Reports Q4 EPS $0.88, vs. Street Est of $0.83 MT
More news

Latest transcript on Organon & Co.

Logo Organon & Co.
Organon & Co., Q4 2023 Earnings Call, Feb 15, 2024
More transcripts

Analyst Recommendations on Organon & Co.

Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating MT
Goldman Sachs Adjusts Price Target on Organon to $18 From $16, Keeps Neutral Rating MT
Piper Sandler Adjusts Organon & Co.'s Price Target to $22 From $32, Maintains Overweight Rating MT
Goldman Sachs Downgrades Organon to Neutral From Buy, Cuts Price Target to $16 From $33 MT
Morgan Stanley Adjusts Price Target on Organon to $22 From $27, Maintains Equal-Weight Rating MT
More recommendations

Press releases Organon & Co.

Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024 BU
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints BU
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health AQ
Organon Announces HADLIMA Has Been Exclusively Selected by the US Department of Veterans Affairs, Replacing HUMIRA on Its National Formulary AQ
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary BU
More press releases

News in other languages on Organon & Co.

El estudio clínico comparativo de fase 3 del candidato a biosimilar de Prolia ® y Xgeva ® (denosumab) HLX14 alcanzó los criterios de valoración primarios
Klinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre Endpunkte
L'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primaires
Philips : une nouvelle directrice financière en octobre
Organon et Lilly concluent un accord de commercialisation en Europe pour deux médicaments contre la migraine
More news

Quotes and Performance

1 day+0.71%
1 week+4.10%
Current month-1.33%
1 month+2.37%
3 months+10.88%
6 months+21.16%
Current year+28.64%
More quotes

Highs and lows

1 week
17.79
Extreme 17.79
18.75
1 month
17.33
Extreme 17.33
18.93
Current year
13.65
Extreme 13.65
19.08
1 year
10.84
Extreme 10.835
24.79
3 years
10.84
Extreme 10.835
39.48
5 years
10.84
Extreme 10.835
39.48
10 years
10.84
Extreme 10.835
39.48
More quotes

Managers and Directors - Organon & Co.

Managers TitleAgeSince
Kevin Ali CEO
 Chief Executive Officer 63 21-06-01
Matthew Walsh DFI
 Director of Finance/CFO 57 21-06-01
Juan Camilo Arjona Ferreira CTO
 Chief Tech/Sci/R&D Officer 54 23-09-04
Members of the board TitleAgeSince
Rochelle Lazarus BRD
 Director/Board Member 76 21-06-01
Carrie Cox CHM
 Chairman 66 21-06-01
Robert Essner BRD
 Director/Board Member 76 21-06-01
More insiders

ETFs positioned on Organon & Co.

Name Weight AuM 1st Jan change Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
15.92% 215 M€ +10.68% -
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED ETF First Trust AlphaDEX U.S. Health Care Sector Index ETF - CAD Hedged
1.71% 2 M€ +6.77%
More ETFs positioned on Organon & Co.

Quotes

Date Price Change Volume
24-04-26 18.55 +0.71% 2,049,767
24-04-25 18.42 -1.55% 1,541,861
24-04-24 18.71 +1.03% 1,999,344
24-04-23 18.52 +2.89% 1,699,256
24-04-22 18 +1.01% 1,551,049

Delayed Quote Nyse, April 26, 2024 at 04:00 pm

More quotes

Company Profile

Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. The Company’s Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.
Sector
Pharmaceuticals
Calendar
2024-05-02 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Organon & Co.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
18.55 USD
Average target price
21.5 USD
Spread / Average Target
+15.90%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ORGANON & CO. Stock Organon & Co.
+28.64% 4.77B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. OGN Stock